Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer
dc.contributor.author | Han, X | |
dc.contributor.author | Zhao, L | |
dc.contributor.author | Xiang, W | |
dc.contributor.author | Qin, C | |
dc.contributor.author | Miao, B | |
dc.contributor.author | McEachern, D | |
dc.contributor.author | Wang, Y | |
dc.contributor.author | Metwally, H | |
dc.contributor.author | Wang, L | |
dc.contributor.author | Matvekas, A | |
dc.contributor.author | Wen, B | |
dc.contributor.author | Sun, D | |
dc.contributor.author | Wang, S | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2024-01-23T21:15:17Z | |
dc.date.available | 2024-01-23T21:15:17Z | |
dc.date.issued | 2021-09-09 | |
dc.identifier.issn | 0022-2623 | |
dc.identifier.issn | 1520-4804 | |
dc.identifier.uri | https://www.ncbi.nlm.nih.gov/pubmed/34431670 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/192129 | en |
dc.description.abstract | Proteolysis targeting chimera (PROTAC) small-molecule degraders have emerged as a promising new type of therapeutic agents, but the design of PROTAC degraders with excellent oral pharmacokinetics is a major challenge. In this study, we present our strategies toward the discovery of highly potent PROTAC degraders of androgen receptor (AR) with excellent oral pharmacokinetics. Employing thalidomide to recruit cereblon/cullin 4A E3 ligase and through the rigidification of the linker, we discovered highly potent AR degraders with good oral pharmacokinetic properties in mice with ARD-2128 being the best compound. ARD-2128 achieves 67% oral bioavailability in mice, effectively reduces AR protein and suppresses AR-regulated genes in tumor tissues with oral administration, leading to the effective inhibition of tumor growth in mice without signs of toxicity. This study supports the development of an orally active PROTAC AR degrader for the treatment of prostate cancer and provides insights and guidance into the design of orally active PROTAC degraders. | |
dc.format.medium | Print-Electronic | |
dc.language | eng | |
dc.publisher | American Chemical Society (ACS) | |
dc.subject | Administration, Oral | |
dc.subject | Androgen Receptor Antagonists | |
dc.subject | Animals | |
dc.subject | Antineoplastic Agents | |
dc.subject | Area Under Curve | |
dc.subject | Biological Availability | |
dc.subject | Drug Delivery Systems | |
dc.subject | Drug Discovery | |
dc.subject | Half-Life | |
dc.subject | Humans | |
dc.subject | Injections, Intravenous | |
dc.subject | Male | |
dc.subject | Mice | |
dc.subject | Microsomes, Liver | |
dc.subject | Molecular Structure | |
dc.subject | Prostatic Neoplasms | |
dc.subject | Receptors, Androgen | |
dc.subject | Structure-Activity Relationship | |
dc.subject | Xenograft Model Antitumor Assays | |
dc.title | Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer | |
dc.type | Article | |
dc.identifier.pmid | 34431670 | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/192129/2/Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor f.pdf | |
dc.identifier.doi | 10.1021/acs.jmedchem.1c00882 | |
dc.identifier.doi | https://dx.doi.org/10.7302/22129 | |
dc.identifier.source | Journal of Medicinal Chemistry | |
dc.description.version | Published version | |
dc.date.updated | 2024-01-23T21:15:13Z | |
dc.identifier.orcid | 0000-0003-0904-220X | |
dc.identifier.orcid | 0000-0002-6406-2126 | |
dc.identifier.orcid | 0000-0002-8782-6950 | |
dc.identifier.volume | 64 | |
dc.identifier.issue | 17 | |
dc.identifier.startpage | 12831 | |
dc.identifier.endpage | 12854 | |
dc.identifier.name-orcid | Han, X; 0000-0003-0904-220X | |
dc.identifier.name-orcid | Zhao, L | |
dc.identifier.name-orcid | Xiang, W | |
dc.identifier.name-orcid | Qin, C | |
dc.identifier.name-orcid | Miao, B | |
dc.identifier.name-orcid | McEachern, D | |
dc.identifier.name-orcid | Wang, Y | |
dc.identifier.name-orcid | Metwally, H | |
dc.identifier.name-orcid | Wang, L | |
dc.identifier.name-orcid | Matvekas, A | |
dc.identifier.name-orcid | Wen, B | |
dc.identifier.name-orcid | Sun, D; 0000-0002-6406-2126 | |
dc.identifier.name-orcid | Wang, S; 0000-0002-8782-6950 | |
dc.working.doi | 10.7302/22129 | en |
dc.owningcollname | Internal Medicine, Department of |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.